# Compare AOD-9604, MOTS-c, and Retatrutide — Private Peptides

> A side-by-side clinical comparison of three Metabolic & Weight Research peptides — AOD-9604, MOTS-c, and retatrutide — across mechanism, evidence stage, regulatory status, and the key caution for each.

How a hormone fragment, a mitochondrial signal, and an engineered triple agonist differ in mechanism, human evidence, and what to watch.

## The short version

This page lines up [AOD-9604](/aod-9604), [MOTS-c](/mots-c), and [retatrutide](/retatrutide) side by side on the dimensions that matter for reading metabolic-peptide research: mechanism, most-studied application, evidence stage, administration route studied, regulatory status, and the single caution that matters most for each. The short read: all three are studied for metabolic regulation, but they sit at very different points on the frame this desk uses — from a narrow hormone fragment with a failed human obesity trial, through a mitochondrial signal with real mechanism but no completed human efficacy trial, to a fully engineered triple agonist with the largest reported Phase 2 weight-loss figures and no approval yet. None of this is medical advice, and no dose is recommended here.

## The comparison matrix

| Dimension | AOD-9604 | MOTS-c | Retatrutide |
| --- | --- | --- | --- |
| Origin | Synthetic fragment of human growth hormone (residues 177-191) | Peptide encoded inside the mitochondrial genome (MT-RNR1) | Fully engineered synthetic peptide, GIP-based backbone |
| Primary mechanism | ACC inhibition + beta-3 adrenergic receptor upregulation in fat tissue [4][7] | AMPK activation via the folate cycle; direct CK2 binding [8][12] | Triple agonism at GLP-1R, GIPR, and GCGR [14] |
| Most-studied in | Rodent fat metabolism; human obesity trials; preclinical osteoarthritis | Mouse muscle/metabolism; human biomarker association in hemodialysis | Obesity, type 2 diabetes, metabolic liver disease |
| Evidence stage | Large preclinical base; ~900-subject human safety program; efficacy not established [3] | Strong mechanistic/animal base; one human observational cohort [9]; no human efficacy trial | Phase 2 complete across three indications [15][16][17]; Phase 3 ongoing |
| Administration studied | Oral (human trials) and intraperitoneal/subcutaneous (animal) [2][3] | Not established in humans; animal dosing only | Once-weekly subcutaneous injection [16] |
| Regulatory status | Not approved; obesity program discontinued | Not approved; research-chemical only | Investigational; not approved anywhere as of mid-2026 |
| Key caution | Preclinical mechanism did not translate to human weight loss | No human efficacy trial exists; do not extrapolate from mice | Unverified supply outside trials; dose-dependent heart-rate increase |

## Mechanism

The three work through unrelated biology. AOD-9604 acts locally on fat tissue — slowing fat synthesis via acetyl-CoA carboxylase inhibition and raising beta-3 adrenergic receptor expression to increase fat burning [4][7]. MOTS-c acts through a cellular energy-sensing switch, AMPK, reached via the folate cycle, with a newly identified direct target in casein kinase 2 that behaves differently in muscle versus fat [8][12]. Retatrutide acts on three separate hormone receptors at once — GLP-1, GIP, and glucagon — engineered with deliberately uneven potency at each [14]. None of the three overlaps mechanistically with either of the other two, which is exactly why comparing them clarifies rather than blurs the picture: each represents a genuinely different lever on metabolism.

## Most-studied application

AOD-9604's largest body of work is a human obesity trial program (roughly six trials, ~900 subjects) plus a separate, unrelated preclinical line in osteoarthritis [1][3]. MOTS-c's literature is overwhelmingly mouse and cell work, with one substantial human data point: an observational cardiovascular/mortality association in hemodialysis patients [9]. Retatrutide has the most conventional pharmaceutical development path of the three — structured Phase 2 trials in obesity, type 2 diabetes, and metabolic liver disease, each with defined endpoints and hundreds of participants [15][16][17].

## Evidence stage

This is where the three separate most sharply. AOD-9604 has a completed human trial program that answered its question — safety looked good, efficacy did not clear the bar, and the program was discontinued. MOTS-c has never had a completed human efficacy trial; its human evidence is a biomarker association, not an interventional result [9]. Retatrutide has completed Phase 2 across three indications and is in Phase 3, the furthest along of the three toward a possible approval, but still without the confirmatory data an approval requires [15][16][17]. A reader should not treat "more clinical trials published" as automatically "more proven" — AOD-9604 has the most human trial volume of the three and the weakest efficacy result.

## Administration studied

AOD-9604's human trials used oral dosing, while its animal mechanism work used intraperitoneal and subcutaneous routes [2][3]. MOTS-c has no established human route or dose; all documented administration is in animal studies. Retatrutide's clinical program uses once-weekly subcutaneous injection exclusively, made possible by its fatty-acid-driven extended half-life [16]. This desk does not provide administration, reconstitution, or dosing guidance for any of the three; where a dose appears above, it is the dose used in the cited study, not a recommendation.

## Regulatory and approval status

None of the three compounds is an approved medicine. AOD-9604's obesity development program was discontinued after failing its primary human endpoint; it is currently sold only as a research chemical, and its 503A compounding eligibility was under FDA review as of late 2024. MOTS-c has never entered a pharmaceutical approval pathway and is sold only for laboratory research. Retatrutide is the only one of the three still inside active pharmaceutical development — Phase 3 trials are underway — but it remains unapproved by any regulator as of mid-2026, and gray-market material sold outside that trial program carries no verified identity or purity.

## Key caution

Each compound carries a distinct defining caveat. For AOD-9604, it is the gap between a clean preclinical mechanism and a human trial program that did not demonstrate weight loss — a caution against reading rodent data as a human promise [4][6]. For MOTS-c, it is the near-total absence of human efficacy data: what exists is a real but narrow observational association, not proof that giving anyone MOTS-c changes an outcome [9]. For retatrutide, it is the combination of unverified gray-market supply and a documented, dose-dependent heart-rate increase whose long-term cardiovascular implications are still being studied in an ongoing trial [16]. Read together, the pattern across this desk is the same one that runs through metabolic-peptide research generally: mechanistic promise is common, and confirmed human benefit is scarce and hard-won.

---

Private Peptides is filed like a clinician's briefing, not a chart note: evidence in, strength labeled, and no dose is ever recommended.